Advestra advises German Equity Partners IV on Sale of Swiss Healthcare Group Uroviva to Affidea

Advestra advised Ger­man Equity Part­ners IV, a fund man­aged by the inde­pend­ent Ger­man invest­ment com­pany ECM Equity Cap­it­al Man­age­ment, and oth­er sellers on the sale of Uroviva group, a lead­ing pro­vider of med­ic­al ser­vices in the field of uro­logy, gyneco­logy and onco­logy in Switzer­land, to Affidea, a lead­ing pan-European pro­vider of spe­cial­ist health­care ser­vices includ­ing can­cer care, advanced dia­gnost­ic ima­ging and com­munity-based poly­clin­ics, backed by the lis­ted invest­ment hold­ing com­pany Groupe Bruxelles Lambert.

Advestra acted as Swiss leg­al coun­sel to the sellers in this trans­ac­tion. The team included Beda Kaufmann, Alex­an­der von Jein­sen, Gök­tuğ Gür­büz, Angelika Kre­mer, Anna Capaul, Sil­van Bie­der­mann, Annina Ham­mer, Lina Eis­en­hut and Jill Iten (all Cor­por­ate | M&A and/​or Fin­ance) and Céline Mar­tin (Tax).